公开(公告)号：EP2854850A2

公开(公告)日：2015-04-08

申请号：EP13793069.9

申请日：2013-05-28

申请人： Sloan Kettering Institute For Cancer Research

发明人： KOLESNICK, Richard ,  ROTOLO, Jimmy

IPC分类号： A61K39/395 ,  A61K38/00 ,  A61P1/00 ,  A61P1/04 ,  A61P37/02 ,  A61P37/06

CPC分类号： A61K39/39533 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/55 ,  A61K39/39541 ,  A61K45/06 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/76 ,  A61K2300/00

摘要： It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.

公开(公告)号：EP2152287B1

公开(公告)日：2014-04-02

申请号：EP08755086.9

申请日：2008-05-06

申请人： Sloan Kettering Institute For Cancer Research

发明人： ROTOLO, Jimmy ,  KOLESNICK, Richard ,  PASQUALINI, Renate ,  ARAP, Wadih

IPC分类号： A61K38/00 ,  C07K16/28

CPC分类号： A61K31/55 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/40 ,  C07K16/44

摘要： We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

公开(公告)号：EP2152287A2

公开(公告)日：2010-02-17

申请号：EP08755086.9

申请日：2008-05-06

申请人： Sloan Kettering Institute For Cancer Research

发明人： ROTOLO, Jimmy ,  KOLESNICK, Richard ,  PASQUALINI, Renate ,  ARAP, Wadih

IPC分类号： A61K38/00

CPC分类号： A61K31/55 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/40 ,  C07K16/44

摘要： We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

摘要翻译： 我们已经发现，施用抗神经酰胺抗体治疗并预防由细胞溶解性T淋巴细胞（CTL）介导的一系列疾病 - 诱导的杀伤和内皮微血管的损伤，包括放射诱导的GI综合征，移植物抗宿主病，炎性疾病和 自身免疫性疾病 我们还发现了新的抗神经酰胺单克隆抗体，其优选以人源化形式治疗或治疗这些疾病。